Market Place
Sourcing Support
Secura Bio to Present Copiktra® Data at ASH 2024
06 Nov 2024 //
GLOBENEWSWIRE
Secura Bio to keep offering blood cancer drug despite negative ODAC vote
23 Mar 2023 //
ENDPTS
Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib
09 Jan 2023 //
PR NEWSWIRE
FDA threatens to clamp down on another PI3K blood cancer drug—a full approval
23 Sep 2022 //
FIERCEPHARMA
FDA Warns of Increased Mortality Risk With Duvelisib
01 Jul 2022 //
MEDPAGETODAY
PI3K inhibitor hit with an increased death risk warning from FDA
01 Jul 2022 //
ENDPTS
SECURA BIO ANNOUNCES PRESENTATION OF COPIKTRA DATA FOR PTCL
14 Dec 2021 //
PRNEWSWIRE
Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma
03 Dec 2021 //
PRNEWSWIRE
COPIKTRA® (duvelisib) Receives EMA for the Treatment
09 Jun 2021 //
PRNEWSWIRE
Secura Bio Announces Enrollment Completion of the COPIKTRA®
08 Apr 2021 //
PRNEWSWIRE
COPIKTRA® (duvelisib) Receives Positive CHMP Opinion for the Treatment
01 Apr 2021 //
PRNEWSWIRE
Five new meds recommended in March CHMP decisions
29 Mar 2021 //
PHARMATIMES
Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio
30 Sep 2020 //
BIOSPACE
Secura Bio Completes Acquisition of Global Rights to Oncology Drug Copiktra®
30 Sep 2020 //
PRNEWSWIRE
Verastem Oncology Announces Dosing of 1st Patient CSPC’s Chinese Study COPIKTRA®
29 Jan 2020 //
BUSINESSWIRE
Verastem Oncology Presents Ph2 PRIMO Study Data Evaluating Duvelisib
09 Dec 2019 //
BUSINESSWIRE
Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib
06 Nov 2019 //
BUSINESSWIRE
Pushing to Improve Immunotherapies, c Raises $85 Million in Series B
04 Oct 2019 //
BIOSPACE
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA
03 Oct 2019 //
BIOSPACE
FDA Issues 53 Product-Specific Guidances to Help With Generic Drug Development
17 Sep 2019 //
RAPS
Verastem Oncology out-licenses Copiktra
25 Jul 2019 //
THE PHARMALETTER
15 new cancer drugs debuted in 2018—along with one big leap in drug spending
31 May 2019 //
FIERCE PHARMA
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data
16 May 2019 //
BUSINESSWIRE
The 2018 breakdown on a chart-topping set of new drug approvals
02 Jan 2019 //
ENDPTS
Catalent & Verastem Oncology Partner on Newly Launched COPIKTRA™ (duvelisib) Capsules
16 Oct 2018 //
BUSINESS INSIDER
Verastem Oncology Announces Pricing of $150 Million of Convertible Notes
12 Oct 2018 //
BIOSPACE
CSPC Pharma, Verastem sign license agreement for cancer treatment
05 Oct 2018 //
BIOSPECTRUM
Belgian investors back Spanish orphan drug biotech; Verastem scores China deal
26 Sep 2018 //
ENDPTS
CSPC Pharma, Verastem Sign Exclusive License Agreement for COPIKTRA™ (duvelisib) in China
25 Sep 2018 //
BUSINESSWIRE
US clears Verastem’s Copiktra for blood cancers
25 Sep 2018 //
PHARMA TIMES
Cha-ching: Small biotechs write some of America`s biggest paychecks
07 Aug 2018 //
FIERCE PHARMA
Novartis punts a late-stage PI3K drug to China’s biotechs
12 Jul 2018 //
ENDPTS
ASCO: Roche punts taselisib after weak data, severe side effects
04 Jun 2018 //
FIERCE BIOTECH
Roche dumps PhIII taselisib after harsh side effects for breast cancer
03 Jun 2018 //
ENDPTS
Verastem Oncology to Present Scientific Data Supporting Duvelisib & Defactinib
21 May 2018 //
BUSINESSWIRE
Verastem takes AbbVie’s blood cancer castoff to the FDA
08 Feb 2018 //
ENDPTS
Verastem Announces Regulatory Strategy for Duvelisib NDA Following Guidance, FDA
31 Oct 2017 //
BUSINESS-STANDARD
Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement
28 Jun 2016 //
PR NEWSWIRE
Infinity Pharma back under a cloud after duvelisib disappoints in PhII
15 Jun 2016 //
FIERCE BIOTECH
